STOCK TITAN

Vericel Corp - VCEL STOCK NEWS

Welcome to our dedicated news page for Vericel (Ticker: VCEL), a resource for investors and traders seeking the latest updates and insights on Vericel.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Vericel's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Vericel's position in the market.

Rhea-AI Summary
Vericel Corporation (NASDAQ:VCEL) reported a 23% increase in total revenue to $65.0 million for the fourth quarter of 2023, with adjusted EBITDA growth of 50%. Full-year 2023 saw a 20% revenue growth to $197.5 million. The company provided guidance for 2024 with expected total revenue of $237 to $241 million and a gross margin of 70%.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.44%
Tags
-
Rhea-AI Summary
Vericel Corporation (VCEL) executives to participate in a fireside chat at a healthcare conference. The webcast will be available on the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.17%
Tags
conferences
-
Rhea-AI Summary
Vericel Corporation (NASDAQ:VCEL) will report its Q4 and full-year 2023 financial results on February 29, 2024. The company will discuss financial results and business highlights in a conference call and webcast.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.81%
Tags
conferences earnings
Rhea-AI Summary
Vericel Corporation (VCEL) CEO to present at Canaccord Genuity Musculoskeletal Conference on February 12, 2024. The webcast will be available on the company's Investor Relations website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.77%
Tags
conferences
-
Rhea-AI Summary
Vericel Corporation (VCEL) Expects 20% Total Revenue Growth to $197.5M, 25% Growth in MACI Revenue, and 31% Growth in Burn Care Revenue in Fourth Quarter
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.24%
Tags
-
Rhea-AI Summary
Vericel Corporation (VCEL) to present at 42nd Annual J.P. Morgan Healthcare Conference. Webcast available on Investor Relations section of the Vericel Corporation website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.9%
Tags
conferences
Rhea-AI Summary
Vericel Corporation (NASDAQ:VCEL) reports record third quarter revenue of $45.6 million, an 18% growth versus the prior year. MACI revenue grew by 21% to $37.6 million. Full-year 2023 revenue guidance raised to $192.5-197.5 million. Positive results from NexoBrid Phase 3 DETECT study published in the Journal of Burn Care & Research.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.4%
Tags
-
Rhea-AI Summary
Vericel Corporation (NASDAQ:VCEL) will have its President and CEO and CFO present at the Stephens Annual Investment Conference on November 15, 2023. The webcast of the presentation will be available on the Investor Relations section of the Vericel Corporation website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1%
Tags
conferences
-
Rhea-AI Summary
Vericel Corporation (NASDAQ:VCEL) will report its third-quarter 2023 financial results on November 8, 2023. The company's management will host a conference call and webcast to discuss the results and business highlights.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.08%
Tags
conferences earnings
Rhea-AI Summary
Vericel Corporation announces positive results from Phase 3 DETECT study on NexoBrid treatment for severe burns, with over 90% of patients achieving complete eschar removal and reduced need for surgery.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.03%
Tags
Vericel Corp

Nasdaq:VCEL

VCEL Rankings

VCEL Stock Data

2.32B
44.66M
0.84%
112.24%
9.08%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
US
Cambridge

About VCEL

about vericel founded in 1989, vericel (formerly aastrom biosciences), is dedicated to the development of patient-specific expanded cellular therapies for use in the treatment of patients with severe diseases and conditions. the company markets two cell therapy products in the united states, carticel® (autologous cultured chondrocytes), an autologous chondrocyte implant for the treatment of cartilage defects in the knee and epicel® (cultured epidermal autografts), a permanent skin replacement for the treatment of patients with deep dermal or full thickness burns greater than or equal to 30% of total body surface area. vericel is also developing maci, a third-generation autologous chondrocyte implant for the treatment of cartilage defects in the knee, and ixmyelocel-t, a patient specific multicellular therapy for the treatment of advanced heart failure due to ischemic dilated cardiomyopathy (dcm). to fulfill vericel’s mission of helping people with severe diseases and conditions rea